The increased use of prostate-specific antigen (PSA) in screening for preclinical disease
after 1985 is thought to be a major determinant of the changing patterns in prostate cancer …

PURPOSE: We describe trends in prostate cancer mortality from 1980 to 1997, before and
after the introduction of serum prostate specific antigen (PSA) testing to the community …

Prostate cancer incidence and mortality rates vary worldwide. In the United States, prostate
cancer is the most common malignancy affecting men and is the second-leading cause of …

We reviewed prostate cancer trends prior to and during the prostate-specific antigen (PSA)
era using data reported from population-based tumor registries in the United States. On the …

PURPOSE: In the last 2 decades there has been increasing awareness of and research on
prostate cancer. We considered prostate cancer in the context of other major causes of …

Objective. The purpose of this study was to compare prostate cancer incidence and mortality
trends between the United States and Canada over a period of approximately 30 years …

PURPOSE: We assess the influence of prostate specific antigen screening on trends in
mortality rates in patients with prostate cancer. MATERIALS AND METHODS: The incidence …

Objectives. The use of prostate-specific antigen (PSA) to screen for prostate cancer remains
controversial. Although it is still too early to measure directly the effects of PSA screening on …

The incidence and mortality of prostate cancer is highly varied among populations and
especially among blacks and whites. The incidence rates of all American populations have …

Changes in prostate cancer detection and patterns of care may account for recent declines
in prostate cancer mortality in the United States.